EW - Edwards Lifesciences Corporation
| Previous Close | 238.58 |
| Open | 239.81 |
| Bid | 0.00 x 1200 |
| Ask | 0.00 x 1300 |
| Day's Range | 238.02 - 239.97 |
| 52 Week Range | 163.08 - 247.64 |
| Volume | 1,357,816 |
| Avg. Volume | 1,179,953 |
| Market Cap | 49.773B |
| Beta (5Y Monthly) | 0.77 |
| PE Ratio (TTM) | 65.52 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Edwards Lifesciences (EW) Stock Sinks As Market Gains: What You Should Know
Edwards Lifesciences (EW) closed the most recent trading day at $231.46, moving -0.67% from the previous trading session.
- Investor's Business Daily
Stocks To Watch: Life Sciences Leader Repligen Tests New Buy With 84% Growth
Boosted by average EPS growth of 84% over the last three quarters, life sciences leader and biologic drugmaker Repligen is now testing a new buy point.
- Investopedia
Top Health Care Stocks for January 2020
These are the health care stocks with the best value, fastest growth, and most momentum for January.
- Simply Wall St.
Is Edwards Lifesciences Corporation (NYSE:EW) Excessively Paying Its CEO?
In 2000 Mike Mussallem was appointed CEO of Edwards Lifesciences Corporation (NYSE:EW). This analysis aims first to...
- Zacks
Edwards Lifesciences (EW) Stock Moves -0.5%: What You Should Know
In the latest trading session, Edwards Lifesciences (EW) closed at $234.61, marking a -0.5% move from the previous day.
- Zacks
Edwards (EW) Rides on Innovation Despite Regulatory Issues
Edwards Lifesciences' (EW) HemoSphere all-in-one monitoring platform is gaining momentum on the back of a strong rollout that sees a full-market launch.
- Insider Monkey
How Did Edwards Lifesciences Corporation (EW) Perform In Comparison to Hedge Fund Favorites in 2019?
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged in 2019. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 57%. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted returns. That's why we weren't […]
- Zacks
Top Stock Picks for the Week of Dec 23, 2019
Tracey Ryniec takes a look at two Zacks Rank 1 (Strong Buy) stocks.
- Zacks
Zacks Market Edge Highlights: Edwards Lifesciences, Sony, Alibaba, State Street and Exxon
Zacks Market Edge Highlights: Edwards Lifesciences, Sony, Alibaba, State Street and Exxon
- Investor's Business Daily
Dow Jones Futures: Will Star Wars Force Disney Lower? Five Stocks Near Buy Points
Dow futures: Will a not-so-forceful Star Wars lift or sink Disney stock? Also, Applied Materials, KLA, Inphi, Keysight Technologies and Edwards Lifesciences have new buy points.
- Zacks
The Zacks Analyst Blog Highlights: Uber, AES, CIRCOR International, Edwards Lifesciences and Zynerba Pharmaceuticals
The Zacks Analyst Blog Highlights: Uber, AES, CIRCOR International, Edwards Lifesciences and Zynerba Pharmaceuticals
- Zacks
Investing Outlook for 2020: Recession or Not?
Some stock market bears have been waiting for a US recession for four years. Is 2020 the year they will finally be right or will they have to throw in the towel and join the bull's party?
- Zacks
Uber Is Formally into the Staffing Business
Uber Works makes Uber more like the technology platform it claims to be and less the ride-hailing service that we recognize it as.
- Zacks
Edwards Lifesciences (EW) Upgraded to Strong Buy: Here's Why
Edwards Lifesciences (EW) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks
Edwards Lifesciences (EW) Dips More Than Broader Markets: What You Should Know
Edwards Lifesciences (EW) closed at $235.63 in the latest trading session, marking a -0.96% move from the prior day.
- Zacks
Here's Why You Should Hold on to Allscripts Stock for Now
Allscripts (MDRX) is gaining steadily from strategic acquisitions and solid prospects in Sunrise EHR platform. However, integration risks remain a woe.
- Zacks
Here's Why You Should Bet on Integer Holdings Stock Now
Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.
- Zacks
Here's Why You Should Invest in Cardinal Health Stock Now
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment.
- Zacks
NextGen Healthcare Boosts Patient Care With CHC Strategies
NextGen Healthcare (NXGN) is likely to boost presence in health management with CHC Strategies delivering quality medical care through the company's Population Health platform.
- Zacks
Here's Why You Should Retain NextGen Healthcare for Now
NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.
- Zacks
Edwards Lifesciences (EW) Plans Strong Long-Term TAVR Growth
Within TAVR, Edwards (EW) expects global TAVR opportunity to exceed $7 billion by 2024.
- Zacks
Here's Why You Should Hold on to Cerner (CERN) Stock Now
Cerner (CERN) is gaining traction from prudent strategic deals and big data based EHR system. However, weak margins remain a woe.
- Yahoo Finance Video
Stakeholder capitalism: how one health company is treating investors and employees equally
Edwards Lifesciences uses special equipment catered to fighting heart disease while also focusing on stakeholder capitalism. This enables Edwards Lifesciences to thrive financially and benefit a wider community beyond shareholders. Yahoo Finance’s Adam Shapiro and Julie Hyman discuss with Edwards Lifesciences CEO Mike Mussallem, KPMG Chief Economist Constance Hunter and Just Capital CEO Martin Whittaker on On the Move.
